Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and radiofrequency ablation treatment with Hepatocellular Carcinoma
ChiCTR-IPR-17011038Phase 4Recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Apr 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of Rivoceranib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: progression-free survival. Started Apr 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-IPR-17011038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17011038.